A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding “Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer” by Chen et al.

Use of effective but relatively toxic anthracyclines remains one of the most controversial issues in the treatment of early breast cancer (eBC). A recent meta-analysis showed a significantly better invasive (iDFS) and distant disease-free survival after concurrent anthracycline-taxane vs. taxane-based chemotherapy in HR-positive/HER2-negative eBC.1 Recently, Chen and colleagues demonstrated that patients with node-negative, HR-positive/HER2-negative early breast cancer (eBC), and high…